The 180-day IPO lock-up period of Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company developing therapies for the treatment of high-impact, difficult-to-treat cancers, expires today (Feb.10, 2025).
The company's lead drug candidate is an intravenous injection solution of Elraglusib, which in combination with gemcitabine/nab-paclitaxel (GnP) is being evaluated in a phase II trial in first-line treatment of metastatic pancreatic ductal adenocarcinoma, dubbed Actuate-1801 Part 3B.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com